PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
35341315-9	2022	To understand why the beta-lactamase inhibitor vaborbactam is less affected by the D179 variants than avibactam, we determined the crystal structure of D179N KPC-2 in complex with vaborbactam, which revealed wild-type KPC-2-like vaborbactam-active site interactions.	vaborbactam	47-58	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	158-163
35341315-10	2022	Overall, the structural results regarding KPC-2 D179 variants revealed various degrees of destabilization of the Omega loop that contribute to ceftazidime-avibactam resistance, possible substrate-assisted catalysis of ceftazidime, and meropenem and meropenem-vaborbactam susceptibility.	vaborbactam	259-270	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	42-47
31712199-7	2020	Importantly, vaborbactam inhibited KPC-2, KPC-3, BKC-1 and SME-2 carbapenemases at 1:1 stoichiometry, while these numbers were higher for other class A and C enzymes.	vaborbactam	13-24	UBA domain containing 1	Homo sapiens	35-40
32312773-3	2020	We demonstrate that KvrA loss reduces OmpK35 and OmpK36 porin production, which confers reduced susceptibility to meropenem/vaborbactam in a KPC-3 producing K. pneumoniae isolate.	vaborbactam	124-135	KPC-3	Klebsiella pneumoniae	141-146
33017041-4	2020	Multiple in vitro studies evaluating isolates from various geographic regions, and over different time periods, have demonstrated the high potency of meropenem-vaborbactam against organisms containing KPC2 and KPC3.	vaborbactam	160-171	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	201-205
33017041-4	2020	Multiple in vitro studies evaluating isolates from various geographic regions, and over different time periods, have demonstrated the high potency of meropenem-vaborbactam against organisms containing KPC2 and KPC3.	vaborbactam	160-171	KPC-3	Klebsiella pneumoniae	210-214
32660988-2	2020	We show that four steps: ompK36 and ramR mutation plus carriage of OXA-232 and KPC-3-D178Y variant beta-lactamases confer ceftazidime/avibactam and meropenem/vaborbactam resistance when both pairs are used together.	vaborbactam	158-169	KPC-3	Klebsiella pneumoniae	79-84
32015028-0	2020	Potency of Vaborbactam is Less Affected than Avibactam in Strains Producing KPC-2 Mutations that Confer Resistance to Ceftazidime-Avibactam.	vaborbactam	11-22	KPC-2	Pseudomonas aeruginosa	76-81
30128699-2	2018	Intravenous meropenem/vaborbactam (Vabomere ) is the first carbapenem/beta-lactamase inhibitor combination approved in the USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis.	vaborbactam	22-33	beta-lactamase	Klebsiella pneumoniae	70-84
30128699-3	2018	Vaborbactam is a potent inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of meropenem against beta-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.	vaborbactam	0-11	beta-lactamase	Klebsiella pneumoniae	166-180
30128699-4	2018	Meropenem/vaborbactam demonstrated excellent in vitro activity against Gram-negative clinical isolates, including KPC- and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae.	vaborbactam	10-21	beta-lactamase	Klebsiella pneumoniae	141-155
29510189-11	2018	Meropenem/vaborbactam had limited activity against MBL-producing isolates (including 49 NDM-, 1 IMP-64- and 2 VIM-producers) and/or oxacillinases (47 OXA-48/-232) that were detected mainly in European countries.	vaborbactam	10-21	mannose-binding lectin family member 3, pseudogene	Homo sapiens	51-54